BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP
November 07 2023 - 7:00AM
Westport, CT, November 7, 2023 (GLOBE
NEWSWIRE) -- BioSig Technologies,
Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical
technology company committed to delivering unprecedented accuracy
and precision to intracardiac signal visualization, announced the
appointment of Frederick Hrkac to the new role of Executive Vice
President, effective as of November 2, 2023. Mr. Hrkac has a
32-year career in medical devices, as an executive and corporate
director, covering much of the globe. Since April 2022, he has
served on the BioSig Board of Directors and as Chairman of the
nominating and corporate governance committee. As a result of his
appointment, Mr Hrkac was replaced by James Klein as a member and
Chairman of the nominating and corporate governance
committee. “Fred is well-known as a key executive leader in
the global medical device industry. He carries an impeccable
reputation and strong track record of success in commercial medtech
operations, highlighted by his contributions to the immense growth
and expansion of BioSense Webster, the med-device businesses of
Johnson & Johnson (“J&J”), Boston Scientific, and other
influential companies,” said Kenneth Londoner, Chairman & CEO
of BioSig. “It’s a great pleasure to welcome Fred from our Board of
Directors to our executive team, where he will work closely with
executive leadership in unlocking the value of our business and
technology and opening doors to new opportunities through his close
contacts around the globe.”
“I am thrilled with the opportunity to bring
BioSig’s groundbreaking technology into the hands of
electrophysiologists with a strategy similar to my work 20 years
ago in introducing novel cardiac navigational technology that
shaped the way atrial fibrillation is treated globally,” said Mr.
Hrkac. “I look forward to working closely with the outstanding
leadership team at BioSig to spur PURE EP™ Platform adoption in
multiple new geographic markets and drive multiple avenues of
potential value creation.”
Mr. Hrkac’s career began at J & J where he
managed the company’s complete portfolio of general surgery and
cardiology/electrophysiology products. He was part of the small
team that started and grew J&J’s businesses in central and
eastern Europe in the 1990’s, driving revenue growth from $22
million to over $500 million in seven years. At Biosense Webster, a
J&J company, Mr. Hrkac was head of global marketing and all
commercial activity outside the U.S., leading the early stages of
the company’s dominance of the electrophysiology market from
2001-2005.
After a 15-year career at J&J, Mr. Hrkac
became president and CEO of Sorin Cardiac Rhythm Management (CRM),
where he led the globalization of the company into regions
including the U.S., Japan, and EMEA. He then became President of
Boston Scientific EMEA, managing a $1.8 billion P&L that
covered the entire Boston Scientific portfolio in more than 65 EMEA
countries.
In 2015, Mr. Hrkac joined Biosensors, a
Singapore-based stent company, where he led the company’s global
commercialization and eventual sale of the Company for over $1
billion in 2018.
Mr. Hrkac currently serves on the board of Serres
in Helsinki, Finland, and Spineart in Geneva, Switzerland as
chairman of the board.
About BioSig Technologies,
Inc.BioSig Technologies is a medical technology
company focused on deciphering the body’s electrical signals,
starting with heart rhythms. By leveraging a first of its kind
combination of hardware and software, we deliver unprecedented
cardiac signal clarity, ending the reliance on ‘mixed signals’ and
‘reading between the lines.’ Our platform technology is addressing
some of healthcare’s biggest challenges—saving time, saving costs,
and saving lives.
The Company’s product, the PURE EP™ Platform, an
FDA 510(k) cleared non-invasive class II device, provides superior,
real-time signal visualization allowing physicians to perform
highly targeted cardiac ablation procedures with increased
procedural efficiency and efficacy.
An estimated, 14.4 million Americans suffer from
cardiac arrhythmias, and the global EP market is projected to reach
$16B in 2028 with an 11.2% growth rate.1
Forward-Looking StatementsThis
press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website
at http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
[1] Global Market Insights, Inc. (2022, March)
For investor relations:
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
For media inquiries:
Katie Freshwater
BioSig Technologies, Inc.
Vice President, Marketing
55 Greens Farms
Westport, CT 06880
kfreshwater@biosigtech.com
203-409-5444, x162
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024